Human NK cells selective targeting of colon cancer-initiating cells: A role for natural cytotoxicity receptors and MHC class i molecules

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 2381-2390

  Tallerico, Rossana ^a,b   Todaro, Matilde ^c   Di Franco, Simone ^c   MacCalli, Cristina ^d   Garofalo, Cinzia ^a   Sottile, Rosa ^a   Palmieri, Camillo ^a   Tirinato, Luca ^a,e   Pangigadde, Pradeepa N ^a,b   La Rocca, Rosanna ^a,e   Mandelboim, Ofer ^f   Stassi, Giorgio ^c   Di Fabrizio, Enzo ^a,e,i   Parmiani, Giorgio ^d   Moretta, Alessandro ^g   Dieli, Francesco ^h   Kärre, Klas ^b   Carbone, Ennio ^a,b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF PALERMO   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^f HEBREW UNIVERSITY   (Israel)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF PALERMO   (Italy)

ⁱ KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL CYTOTOXICITY RECEPTOR; NATURAL KILLER CELL RECEPTOR; PROTEIN P30; PROTEIN P44; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL SURFACE; CELLULAR DISTRIBUTION; COLON ADENOCARCINOMA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE FUNCTION; MOLECULAR RECOGNITION; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SOLID TUMOR; TARGET CELL;

ADENOCARCINOMA; ANIMALS; CELL LINEAGE; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, CONFOCAL; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NEOPLASTIC STEM CELLS; ORGAN SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 84874260704     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1201542     Document Type: Article

References (55)

1. Croker, A. K., and A. L. Allan. 2008. Cancer stem cells: implications for the progression and treatment of metastatic disease. J. Cell. Mol. Med. 12: 374-390.
2. Li, F., B. Tiede, J. Massagué, and Y. Kang. 2007. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 17: 3-14.
3. Luzzi, K. J., I. C. MacDonald, E. E. Schmidt, N. Kerkvliet, V. L. Morris, A. F. Chambers, and A. C. Groom. 1998. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 153: 865-873.
4. Chambers, A. F., A. C. Groom, and I. C. MacDonald. 2002. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2: 563-572.
5. Reya, T., S. J. Morrison, M. F. Clarke, and I. L. Weissman. 2001. Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
6. Shackleton, M. 2010. Normal stem cells and cancer stem cells: similar and different. Semin. Cancer Biol. 20: 85-92.
7. Lobo, N. A., Y. Shimono, D. Qian, and M. F. Clarke. 2007. The biology of cancer stem cells. Annu. Rev. Cell Dev. Biol. 23: 675-699.
8. Moitra, K., H. Lou, and M. Dean. 2011. Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin. Pharmacol. Ther. 89: 491-502.
9. Jemal, A., R. Siegel, E.Ward, T. Murray, J. Xu, C. Smigal, and M. J. Thun. 2006. Cancer statistics, 2006. CA Cancer J. Clin. 56: 106-130.
10. Ricci-Vitiani, L., D. G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle, and R. De Maria. 2007. Identification and expansion of human colon-cancerinitiating cells. Nature 445: 111-115.
11. Dylla, S. J., L. Beviglia, I. K. Park, C. Chartier, J. Raval, L. Ngan, K. Pickell, J. Aguilar, S. Lazetic, S. Smith-Berdan, et al. 2008. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE 3: e2428.
12. Anderson, E. C., C. Hessman, T. G. Levin, M. M. Monroe, and M. H. Wong. 2011. The role of colorectal cancer stem cells in metastatic disease and therapeutic response. Cancers (Basel) 3: 319-339.
13. Sun, J. C., and L. L. Lanier. 2011. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat. Rev. Immunol. 11: 645-657.
14. Farag, S. S., and M. A. Caligiuri. 2006. Human natural killer cell development and biology. Blood Rev. 20: 123-137.
15. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47: 187-376.
16. Björkström, N. K., P. Riese, F. Heuts, S. Andersson, C. Fauriat, M. A. Ivarsson, A. T. Björklund, M. Flodström-Tullberg, J. Michaëlsson, M. E. Rottenberg, et al. 2010. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 116: 3853-3864.
17. Chiesa, S., M. Mingueneau, N. Fuseri, B. Malissen, D. H. Raulet, M. Malissen, E. Vivier, and E. Tomasello. 2006. Multiplicity and plasticity of natural killer cell signaling pathways. Blood 107: 2364-2372.
18. González, S., V. Groh, and T. Spies. 2006. Immunobiology of human NKG2D and its ligands. Curr. Top. Microbiol. Immunol. 298: 121-138.
19. Moretta, A., C. Bottino, M. Vitale, D. Pende, C. Cantoni, M. C. Mingari, R. Biassoni, and L. Moretta. 2001. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19: 197-223.
20. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274.
21. Bottino, C., R. Castriconi, D. Pende, P. Rivera, M. Nanni, B. Carnemolla, C. Cantoni, J. Grassi, S. Marcenaro, N. Reymond, et al. 2003. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 198: 557-567.
22. Fanger, N. A., L. Borges, and D. Cosman. 1999. The leukocyte immunoglobulin-like receptors (LIRs): a new family of immune regulators. J. Leukoc. Biol. 66: 231-236.
23. Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107: 159-166.
24. Kim, S., K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama. 2000. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA 97: 2731-2736.
25. Smyth, M. J., Y. Hayakawa, K. Takeda, and H. Yagita. 2002. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer 2: 850-861.
26. Malmberg, K. J., Y. T. Bryceson, M. Carlsten, S. Andersson, A. Björklund, N. K. Björkström, B. C. Baumann, C. Fauriat, E. Alici, M. S. Dilber, and H. G. Ljunggren. 2008. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol. Immunother. 57: 1541-1552.
27. Lakshmikanth, T., S. Burke, T. H. Ali, S. Kimpfler, F. Ursini, L. Ruggeri, M. Capanni, V. Umansky, A. Paschen, A. Sucker, et al. 2009. NCRs and DNAM- 1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 119: 1251-1263.
28. Carlsten, M., N. K. Björkström, H. Norell, Y. Bryceson, T. van Hall, B. C. Baumann, M. Hanson, K. Schedvins, R. Kiessling, H. G. Ljunggren, and K. J. Malmberg. 2007. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 67: 1317-1325.
29. El-Sherbiny, Y. M., J. L. Meade, T. D. Holmes, D. McGonagle, S. L. Mackie, A. W. Morgan, G. Cook, S. Feyler, S. J. Richards, F. E. Davies, et al. 2007. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cellmediated killing of myeloma cells. Cancer Res. 67: 8444-8449.
30. Carbone, E., P. Neri, M. Mesuraca, M. T. Fulciniti, T. Otsuki, D. Pende, V. Groh, T. Spies, G. Pollio, D. Cosman, et al. 2005. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105: 251-258.
31. Burke, S., T. Lakshmikanth, F. Colucci, and E. Carbone. 2010. New views on natural killer cell-based immunotherapy for melanoma treatment. Trends Immunol. 31: 339-345.
32. Baumann, M., M. Krause, and R. Hill. 2008. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 8: 545-554.
33. Galli, R., E. Binda, U. Orfanelli, B. Cipelletti, A. Gritti, S. De Vitis, R. Fiocco, C. Foroni, F. Dimeco, and A. Vescovi. 2004. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64: 7011-7021.
34. Mazzoleni, S., L. S. Politi, M. Pala, M. Cominelli, A. Franzin, L. Sergi Sergi, A. Falini, M. De Palma, A. Bulfone, P. L. Poliani, and R. Galli. 2010. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 70: 7500-7513.
35. Hu, Y., and G. K. Smyth. 2009. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 347: 70-78.
36. Pende, D., P. Rivera, S. Marcenaro, C. C. Chang, R. Biassoni, R. Conte, M. Kubin, D. Cosman, S. Ferrone, L. Moretta, and A. Moretta. 2002. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62: 6178-6186.
37. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
38. McGinnes, K., G. Chapman, R. Marks, and R. Penny. 1986. A fluorescence NK assay using flow cytometry. J. Immunol. Methods 86: 7-15.
39. Pende, D., S. Parolini, A. Pessino, S. Sivori, R. Augugliaro, L. Morelli, E. Marcenaro, L. Accame, A. Malaspina, R. Biassoni, et al. 1999. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J. Exp. Med. 190: 1505-1516.
40. Di Tomaso, T., S. Mazzoleni, E. Wang, G. Sovena, D. Clavenna, A. Franzin, P. Mortini, S. Ferrone, C. Doglioni, F. M. Marincola, et al. 2010. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin. Cancer Res. 16: 800-813.
41. Das, G., R. La Rocca, T. Lakshmikanth, F. Gentile, R. Tallerico, L. P. Zambetti, J. Devitt, P. Candeloro, F. De Angelis, E. Carbone, and E. Di Fabrizio. 2010. Monitoring human leukocyte antigen class I molecules by micro-Raman spectroscopy at single-cell level. J. Biomed. Opt. 15: 027007.
42. O'Brien, C. A., A. Pollett, S. Gallinger, and J. E. Dick. 2007. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
43. Hanna, J., D. Goldman-Wohl, Y. Hamani, I. Avraham, C. Greenfield, S. Natanson-Yaron, D. Prus, L. Cohen-Daniel, T. I. Arnon, I. Manaster, et al. 2006. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat. Med. 12: 1065-1074.
44. Guldevall, K., B. Vanherberghen, T. Frisk, J. Hurtig, A. E. Christakou, O. Manneberg, S. Lindström, H. Andersson-Svahn, M. Wiklund, and B. Ö nfelt. 2010. Imaging immune surveillance of individual natural killer cells confined in microwell arrays. PLoS ONE 5: e15453.
45. Lopez-Vergès, S., J. M. Milush, B. S. Schwartz, M. J. Pando, J. Jarjoura, V. A. York, J. P. Houchins, S. Miller, S. M. Kang, P. J. Norris, et al. 2011. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 108: 14725-14732.
46. Björkström, N. K., T. Lindgren, M. Stoltz, C. Fauriat, M. Braun, M. Evander, J. Michaëlsson, K. J. Malmberg, J. Klingström, C. Ahlm, and H. G. Ljunggren. 2011. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J. Exp. Med. 208: 13-21.
47. Castriconi, R., A. Daga, A. Dondero, G. Zona, P. L. Poliani, A. Melotti, F. Griffero, D. Marubbi, R. Spaziante, F. Bellora, et al. 2009. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 182: 3530-3539.
48. Avril, T., E. Vauleon, A. Hamlat, S. Saikali, A. Etcheverry, C. Delmas, S. Diabira, J. Mosser, and V. Quillien. 2012. Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells. Brain Pathol. 22: 159-174.
49. Pietra, G., C. Manzini, M. Vitale, M. Balsamo, E. Ognio, M. Boitano, P. Queirolo, L. Moretta, and M. C. Mingari. 2009. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int. Immunol. 21: 793-801.
50. Jewett, A., H. C. Tseng, A. Arasteh, S. Saadat, R. E. Christensen, and N. A. Cacalano. 2012. Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells. Curr. Drug Deliv. 9: 5-16.
51. Tseng, H. C., A. Arasteh, A. Paranjpe, A. Teruel, W. Yang, A. Behel, J. A. Alva, G. Walter, C. Head, T. O. Ishikawa, et al. 2010. Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS ONE 5: e11590.
52. Sandel, M. H., F. M. Speetjens, A. G. Menon, P. A. Albertsson, P. H. Basse, M. Hokland, J. F. Nagelkerke, R. A. Tollenaar, C. J. van de Velde, and P. J. Kuppen. 2005. Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol. Immunol. 42: 541-546.
53. Todaro, M., M. D'Asaro, N. Caccamo, F. Iovino, M. G. Francipane, S. Meraviglia, V. Orlando, C. La Mendola, G. Gulotta, A. Salerno, et al. 2009. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J. Immunol. 182: 7287-7296.
54. Nussbaumer, O., G. Gruenbacher, H. Gander, and M. Thurnher. 2011. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by gd T lymphocytes. Blood 118: 2743-2751.
55. Zitvogel, L., A. Tesniere, and G. Kroemer. 2006. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6: 715-727.